

## Hybrid Organometallic and Enzymatic Tandem Catalysis for Oxyfunctionalisation Reactions

Domesticci, Chiara; Wu, Yinqi; Hilberath, Thomas; Alcalde, Miguel; Hollmann, Frank; Macchioni, Alceo

**DOI**

[10.1002/cctc.202201623](https://doi.org/10.1002/cctc.202201623)

**Publication date**

2023

**Document Version**

Final published version

**Published in**

ChemCatChem

**Citation (APA)**

Domesticci, C., Wu, Y., Hilberath, T., Alcalde, M., Hollmann, F., & Macchioni, A. (2023). Hybrid Organometallic and Enzymatic Tandem Catalysis for Oxyfunctionalisation Reactions. *ChemCatChem*, 15(7), Article e202201623. <https://doi.org/10.1002/cctc.202201623>

**Important note**

To cite this publication, please use the final published version (if applicable). Please check the document version above.

**Copyright**

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

**Takedown policy**

Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.

# Excellence in Chemistry Research

## Announcing our new flagship journal

- Gold Open Access
- Publishing charges waived
- Preprints welcome
- Edited by active scientists



## Meet the Editors of *ChemistryEurope*



**Luisa De Cola**

Università degli Studi  
di Milano Statale, Italy



**Ive Hermans**

University of  
Wisconsin-Madison, USA



**Ken Tanaka**

Tokyo Institute of  
Technology, Japan

# Hybrid Organometallic and Enzymatic Tandem Catalysis for Oxyfunctionalisation Reactions

Chiara Domestici,<sup>[a]</sup> Yinqi Wu,<sup>[b]</sup> Thomas Hilberath,<sup>[b]</sup> Miguel Alcalde,<sup>[c]</sup> Frank Hollmann,<sup>\*,[b]</sup> and Alceo Macchioni<sup>\*,[a]</sup>

Unspecific peroxygenases (UPOs) are promising biocatalysts for oxyfunctionalisation reactions, owing to their simplicity of handling, stability and robustness. A limitation of using UPOs on a large scale is their deactivation in the presence of even rather modest concentrations of H<sub>2</sub>O<sub>2</sub>, requiring a constant and controlled supply of low amount of H<sub>2</sub>O<sub>2</sub>. Herein, we report an organometallic complex [Cp\*Ir(pica)NO<sub>3</sub>] {pica = picolinamide = κ<sup>2</sup>-pyridine-2-carboxamide ion (−1)} **1** capable of efficiently regenerating FMNH<sub>2</sub> from FMN (TOF = 350 h<sup>−1</sup>, 298 K), driven by NaHCOO; FMNH<sub>2</sub>, in turn, spontaneously reacts with O<sub>2</sub> leading to H<sub>2</sub>O<sub>2</sub>. After having studied the compatibility of **1**

with the UPO from *Agrocybe aegerita* (rAaeUPO PaDa-I) and individuated the best experimental conditions, we applied such a hybrid catalytic tandem in some hydroxylation, epoxidation and sulfoxidation reactions. Best performances were obtained by using a 1/rAaeUPO molar ratio of 50. TONs for the biocatalyst of up to 18933 were obtained for the transformation of ethylbenzene derivatives into (*R*)-1-phenylethanol (ee > 99%). 1/rAaeUPO was found to oxidise also *cis*-methyl styrene (TON = 13488), leading exclusively (1*R*,2*S*)-*cis*-methyl styrene oxide (ee > 99%), cyclohexane (TON = 1634) and thioanisole (TON = 1369).

## Introduction

The biocatalytic insertion of oxygen into non-activated organic molecules is attracting an increasing interest in pharmaceutical and industrial chemistry.<sup>[1]</sup> Particularly, enzyme-mediated oxyfunctionalisation reactions, such as hydroxylations or epoxidations, often reach high regio- and enantioselectivity providing alternative routes to the challenging conventional chemical methods. In this context, heme-containing P450 monooxygenases are widely utilised. They form the active oxyferryl-heme species via reductive activation of molecular oxygen.<sup>[2]</sup> Nevertheless, this pathway poses several difficulties such as depend-

ence on costly nicotinamide cofactors, intricate electron transport chains as well as the so-called *Oxygen Dilemma*.<sup>[3]</sup> Some aspects may be solved through protein engineering while others are intrinsically linked to the enzymes' catalytic mechanisms. Fe-monooxygenases depend on single electron transfer processes, thus mediator species, such as ferredoxins and flavodoxins flavins are necessary to convert the hydride provided by NAD(P)H into two successive single electron transfer events to reduce the heme-iron. However, reduced mediators are radical species, and they can direct transfer electrons to dissolved atmospheric oxygen. For NAD(P)H the reaction with O<sub>2</sub> is spin-forbidden, conversely for ferredoxins or flavins it occurs rapidly. Hence, a significant proportion of the reducing equivalents provided by NAD(P)H can get lost in a wasteful uncoupling reaction with O<sub>2</sub>, which leads to H<sub>2</sub>O<sub>2</sub> eventually.<sup>[3]</sup> This hampers the large-scale usage of P450s.

Besides P450s, fungal unspecific peroxygenases (UPOs) have been recently exploited as selective oxyfunctionalisation biocatalysts.<sup>[4]</sup> The first unspecific peroxygenase isolated from the edible mushroom *Agrocybe aegerita* (AaeUPO, E.C. 1.11.2.1) was reported by Ullrich *et al.* in 2004.<sup>[5]</sup> Particularly, its evolved, recombinant variant (rAaeUPO PaDa-I)<sup>[6]</sup> has found considerable interest in the past years. Both enzyme classes utilise an oxyferryl heme as oxygenation species (compound I), however UPOs require only hydrogen peroxide that acts both as final electron acceptor and oxygen source. Thus, compared to P450s, UPOs exhibit a significantly simpler molecular architecture and regeneration scheme enabling the access to the same wide array of reactions and products.<sup>[4]</sup> Particularly, UPOs are able to catalyse the insertions of oxygen into non-activated aliphatic and aromatic C–H bonds and are considered the *Swiss Army Knife* of oxyfunctionalisation chemistry, thanks to the huge portfolio of reactions that they can mediate. Consequently, UPOs are emerging as a promising alternative to the estab-

[a] C. Domestici, Prof. Dr. A. Macchioni

Department of Chemistry,  
Biology and Biotechnology  
University of Perugia and CIRCC  
Via Elce di Sotto, 8  
06123 Perugia (Italy)

E-mail: alceo.macchioni@unipg.it

Homepage: <https://www.unipg.it/personale/alceo.macchioni>

[b] Y. Wu, Dr. T. Hilberath, Prof. Dr. F. Hollmann

Department of Biotechnology  
Delft University of Technology  
Van der Maasweg 9  
2629HZ Delft (The Netherlands)

E-mail: f.hollmann@tudelft.nl

Homepage: <https://www.tudelft.nl/tnw/over-faculteit/afdelingen/biotechnology/research-sections/biocatalysis>

[c] Prof. Dr. M. Alcalde

Department of Biocatalysis  
Institute of Catalysis, CSIC  
C/Marie Curie 2  
28049 Madrid (Spain)

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/cctc.202201623>

© 2023 The Authors. ChemCatChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

lished P450s. However, the H<sub>2</sub>O<sub>2</sub>-dependence of UPOs also bears the challenges of irreversible oxidative enzymatic inactivation.<sup>[7]</sup> Thus, continuous low-level supply or *in situ* generation of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is essential for the stability of peroxygenases.<sup>[8]</sup> To date enzymatic,<sup>[9]</sup> photocatalytic,<sup>[10]</sup> electrochemical,<sup>[11]</sup> transition metal catalysis-based<sup>[12]</sup> and 'miscellaneous'<sup>[13]</sup> *in situ* H<sub>2</sub>O<sub>2</sub> generation approaches have been reported. Among the transition metal-based regeneration methods, Schmid and coworkers have reported the organometallic complex [Cp\*Rh(bpy)(H<sub>2</sub>O)]<sup>2+</sup> for the production of H<sub>2</sub>O<sub>2</sub> from formate, molecular oxygen and FAD as co-catalyst.<sup>[12b]</sup> Furthermore, [Cp\*Rh(bpy)(H<sub>2</sub>O)]<sup>2+</sup> was coupled to cytochrome C in order to catalyse thioanisole sulfoxidation. Already under non-optimised reaction conditions, rhodium-based *in situ* H<sub>2</sub>O<sub>2</sub> generation strategy has shown to be preferable than stoichiometric hydrogen peroxide usage.

A class of organometallic compounds potentially exploitable for H<sub>2</sub>O<sub>2</sub> supply from formate, molecular oxygen and FMN as co-catalyst is constituted by Cp\* iridium pyridincarboxamidate complexes. They are extremely stable, water-soluble, and already used successfully as catalysts for hydrogenation reactions<sup>[14]</sup> with several reducing agents<sup>[15]</sup> in absence of any additives<sup>[16]</sup> and even in cellular media.<sup>[17]</sup> Moreover, they act as efficient catalysts for formic acid dehydrogenation,<sup>[15a,18]</sup> water oxidation, reductive amination of ketones,<sup>[19]</sup> hydrogenolysis of halosilanes,<sup>[20]</sup> and hydrogen peroxide generation<sup>[21]</sup> and they also exhibited good performance as antimicrobial and anti-cancer agents.<sup>[22]</sup>

Herein, we show that the organometallic complex [Cp\*Ir(pica)NO<sub>3</sub>] {pica = picolinamidate = κ<sup>2</sup>-pyridine-2-carboxamide ion (-1)} **1** (Figure 1) is indeed a good catalyst for the H<sub>2</sub>O<sub>2</sub>-regeneration using simple flavin mononucleotide as co-catalyst and formate as hydride source. Furthermore, we disclose a chemoenzymatic tandem combining **1** with rAaeUPO to catalyse oxyfunctionalisation reactions. The feasibility of the proposed chemoenzymatic tandem is demonstrated by the wide portfolio of the reactions it can perform, including aromatic and (cyclo)aliphatic hydroxylation, epoxidation and sulfoxidation.

## Results and Discussion

**1** was synthesised following a modified literature procedure<sup>[15b]</sup> by the reaction of [Cp\*Ir(H<sub>2</sub>O)<sub>3</sub>](NO<sub>3</sub>)<sub>2</sub> and pica in methanol, in the presence of 1 equivalent of KOH. **1** was characterised in






Figure 1. Sketch of [Cp\*Ir(pica)NO<sub>3</sub>] (**1**).

solution by means of <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy (Supporting Information).

Complex **1** was tested as possible catalyst in the reduction of FMN driven by formate [Equation (1)], following the progress of the reaction by means of a UV-Vis spectrophotometer. Particularly, the intensity of the band at 445 nm, diagnostic of FMN, was monitored (Figure S4).




All tests were performed under anaerobic conditions to avoid the spontaneous oxidation of FMNH<sub>2</sub> with atmospheric O<sub>2</sub> [Equation (2)], which might lead to an underestimation of the catalytic activity.



Indeed **1** proved to be an efficient catalyst for reaction (1), always leading to complete consumption of FMN, with a TOF of 350 h<sup>-1</sup> (298 K, [FMN] = 0.1 mM, [HCOONa] = 200 mM, Table S1). The latter was found to be reasonably constant when **1** concentration was changed, suggesting a first-order dependence on catalyst concentration (Table S1 and Figure S5).

The performance of complex **1** compares well with that of [Cp\*Rh(bpy)(H<sub>2</sub>O)]<sup>2+</sup> catalysing FMN and FAD reduction with TOF of 74.3 h<sup>-1</sup> (at 310 K and [HCOONa] = 150 mM) and 28.4 h<sup>-1</sup> (at 303 K; [Cp\*Rh(bpy)(H<sub>2</sub>O)]<sup>2+</sup> = 0.025 mM; [FAD] = 1 mM and [HCOONa] = 500 mM), respectively.<sup>[23]</sup> It is worth mentioning that, to best of our knowledge, only one other Ir complex capable of reducing FMN has been reported in literature,<sup>[24]</sup> utilising H<sub>2</sub> instead of HCOO<sup>-</sup> to *in situ* generate the Ir-H reducing moiety.

As mentioned above, FMNH<sub>2</sub> in presence of atmospheric oxygen spontaneously oxidises to produce hydrogen peroxide (equation 2), thus indicating the possibility of producing H<sub>2</sub>O<sub>2</sub> by the **1**-catalysed regeneration of the cofactor FMNH<sub>2</sub>, driven by HCOONa (Scheme 1). As a matter of fact, a solution of **1** (0.025 mM), HCOONa (200 mM), and FMN (0.1 mM) in phosphate buffer (400 mM, pH 7), under aerobic conditions, generates hydrogen peroxide (> 100 mg/L after 1 h), as semi-quantitatively determined by QUANTOFIX®-Peroxide test sticks. This makes it possible, in principle, to supply a continuous low-level of hydrogen peroxide to the recombinant evolved peroxygenase from *Agroclybe aegerita* (rAaeUPO PaDa-I) for some oxyfunctionalisation reactions, assuming that for every



Scheme 1. *In situ* production of H<sub>2</sub>O<sub>2</sub> by coupling the regeneration of FMNH<sub>2</sub> catalysed by [Cp\*Ir(pica)NO<sub>3</sub>], using formate as hydride source, with the spontaneous reaction of FMNH<sub>2</sub> under aerobic conditions.


equivalent of reduced FMN an equivalent of hydrogen peroxide is produced.

Before testing the 1/*rAaeUPO* tandem in oxyfunctionalisation reaction, a battery of experiments was performed to investigate whether 1 and *rAaeUPO* undergo mutual inhibition. Previous studies have revealed that nucleophilic amino acid residues such as histidine or cysteine can coordinate to transition metal centres resulting in a mutual inhibition of both, the enzymes and the metal catalysts.<sup>[25]</sup> It is worth mentioning here that both, 1 and *rAaeUPO* are intrinsically stable under the given experimental conditions.<sup>[15,26]</sup> Catalyst 1 can be used even under acid and strong oxidising condition, despite its stability is somewhat reduced.<sup>[18c]</sup> Incubation of either of 1 and *rAaeUPO* alone in buffer resulted in no significant reduction of their catalytic activity over several days. In a first set of experiments the residual activity of 1 as FMN<sub>2</sub> regeneration catalyst (reaction 1), in the presence of purified *rAaeUPO* in different molar ratios (50, 100 and 500) and different incubation times (1, 5 and 24 h) (Figure 2a and Table S2) was explored. The degree


of 1-inhibition correlated both with the 1/*rAaeUPO* molar ratio and incubation time. As shown in Figure 2a, the tandem system was severely inhibited when 1/*rAaeUPO* was equal to 50 (residual activity < 22%), suggesting the presence of multiple nucleophilic binding-sites capable to interact with 1. When 1/*rAaeUPO* molar ratio was equal to 100, 1 retained some residual activity (51%, 1 h incubation time), whereas in the case of 1/*rAaeUPO* molar ratios equal to 500, the regeneration catalyst was only slightly inhibited (residual activity > 80%, 1–5 h incubation time and 60% even after 24 h incubation time).

In a second set of experiments, the effect of varying 1 concentration on the activity of *rAaeUPO* in the ABTS assay<sup>[27]</sup> was explored. Results are shown in Figure 2b and Table S3. After one hour of incubation, no decrease of activity was observed for 1 to *rAaeUPO* ratio 50, whereas after 5 h (58%) and 24 h (21%) of incubation a greater inhibition was detected. This may indicate that some of the interacting amino acid residues of *rAaeUPO* are not surface-exposed. The coordination of easily accessible, surface-exposed amino acid residues to 1 is expected to be almost instantaneous while amino acids residing in more central parts of the biocatalyst are only sporadically accessible to the reaction medium (and thereby to 1), therefore limiting the rate of the coordination reaction. Alternatively, protonation/deprotonation equilibria of basic amino acids may also play a role here. Increasing, 1 to *rAaeUPO* molar ratio to 100 the residual activity was drastically reduced (61%, 1 h incubation time; 14% 5 h incubation time) and completely inhibited at 500 1/*rAaeUPO* molar ratio. All these results point towards a mutual inhibition between 1 and *rAaeUPO* that critically depends on 1/*rAaeUPO* molar ratio.


Based on the results illustrated in Figure 2, we decided to perform some oxyfunctionalisation experiments choosing firstly a 1/*rAaeUPO* molar ratio of 25 as a compromise that has the drawback of causing a substantial decrease of the FMN<sub>2</sub> regeneration activity of 1 but allows the performance of *rAaeUPO* to be mostly retained. Ethylbenzene was selected as well-known model substrate (Scheme 2)<sup>[28]</sup> under conditions where it is known to be converted into (*R*)-1-phenylethanol and subsequently overoxidised to acetophenone ([ethylbenzene] = 5 mM; [*rAaeUPO*] = 0.5 μM; buffer: 0.4 M NaPi pH 7 containing 5% v/v acetonitrile; [HCOONa] = 0.2 M; [FMN] = 0.1 mM; [1] = 12.5 μM; 298 K).<sup>[29]</sup> The reaction was followed by means of gas chromatography. The maximum alcohol production was reached after 4 hours, followed by overoxidation of (*R*)-1-phenylethanol to acetophenone as already observed (Figure 3a, Table S4). By means of linear trend fitting, it was possible to obtain an estimation of (*R*)-1-phenylethanol rate production of



**Figure 2.** Residual activity of (a) 1 in the regeneration of FMN<sub>2</sub> driven by HCOONa and (b) *rAaeUPO* in the ABTS assay, as a function of 1/*rAaeUPO* molar ratio, at different incubation times (1 h, black; 5 h, grey; 24 h, white).



**Scheme 2.** Chemoenzymatic oxyfunctionalisation of ethylbenzene promoted by [Cp\*Ir(pica)NO<sub>3</sub>] and *rAaeUPO* catalytic tandem.



**Figure 3.** Time course of the (*R*)-1-phenylethanol (red dots) and acetophenone (blue squares) production from the oxidation of ethylbenzene promoted by **1** and *rAaeUPO* catalytic tandem. Reaction conditions: [ethylbenzene] = 5 mM; [*rAaeUPO*] = 0.5  $\mu$ M; buffer: 0.4 M NaPi pH 7 containing 5% v/v acetonitrile; [HCOONa] = 0.2 M; [FMN] = 0.1 mM; [**1**] = 12.5  $\mu$ M (a), 25  $\mu$ M (b) and 50  $\mu$ M (c); 298 K.

0.16 mM/h. Doubling the concentration of **1** up to 25  $\mu$ M (Figure 3b–c, Table S4), with respect to that of the first trial experiment, led to approximately four times higher alcohol formation rate (0.61 mM/h), with the maximum (*R*)-1-phenylethanol production reached after 2 h; nevertheless, also in this case some overoxidation to the corresponding ketone was observed. At high concentration of **1** (100  $\mu$ M), however, an intermediate formation rate (0.48 mM/h) was observed, but unfortunately the production of both (*R*)-1-phenylethanol and acetophenone stopped already after 2 h. Control experiments carried out under tandem reaction conditions except for the absence of **1** or *rAaeUPO* did not lead to any appreciable amount of product, clearly indicating that the system works synergistically only in tandem (Table S5, SI).

It must be noticed that ethylbenzene conversion was always rather low. This could be due to the presence of acetonitrile (ACN) as co-solvent. Since *rAaeUPO* activity is not impaired by ACN (up to 50% v/v),<sup>[29]</sup> we suspected **1** being inhibited by ACN. Indeed, a FMNH<sub>2</sub> regeneration test with **1** in the presence of 5% v/v acetonitrile (under otherwise the same experimental conditions than for the tandem reaction) exhibited no appreciable catalytic activity. A plausible explanation is that ACN competes with HCOO<sup>−</sup> for coordination to the metal centre and thereby impairs the FAD reduction reaction. In view of this control reaction, it is somewhat surprising that **1** showed some activity in the tandem system.

Identifying a non-coordinating cosolvent, which at the same time is not accepted by *rAaeUPO* as substrate will be a challenge for further optimisation of this reaction setup. However, also biphasic reaction media circumventing water-miscible cosolvents will be attractive for further, preparative-scale applications.

To improve the overall yield of the tandem reaction, we decided to perform an experiment at 50 *rAaeUPO* molar ratio, which appeared to be the optimal value, exploiting methanol as co-solvent instead of ACN ([ethylbenzene] = 20 mM; [*rAaeUPO*] = 1.0  $\mu$ M; [**1**] = 50  $\mu$ M; buffer: 0.4 M NaPi pH 7 containing 4% v/v methanol; [HCOONa] = 0.2 M; [FMN] = 4 mM; 303 K). After 24 h the starting material had been fully consumed and (*R*)-1-phenyl ethanol was obtained with > 99% *ee* (Table S6,

entry 7). We therefore selected methanol as the co-solvent for exploring the scope of the chemoenzymatic system by testing some representative *rAaeUPO* substrates, at 1/*rAaeUPO* molar ratio 50. All the reaction products were quantified by means of gas chromatography. As showed in Table 1, ethylbenzene derivatives a–c were successfully converted into the corresponding alcohol and ketone products. Higher conversion was observed for a (TON = 18933) followed by c (TON = 15702) and b (TON = 8913). For both a and c the overoxidation to the corresponding ketone was quite low (ca 10%), whereas for b it amounted at 50%. In all cases, only the (*R*)-alcohol formation was observed indicating that the oxyfunctionalisation of the substrates was *rAaeUPO*-catalysed and the regeneration catalyst **1** and the enzyme work synergistically in tandem. 1/*rAaeUPO* was able to promote the epoxidation of d (TON = 13488), leading exclusively (1*R*,2*S*)-cis-methyl styrene oxide, demonstrating the applicability of the *in situ* H<sub>2</sub>O<sub>2</sub> regeneration system also for epoxidation reaction.

















Cyclohexane and thioanisole were also oxidised by 1/*rAaeUPO* tandem but with modest performance (Table 1). The observed low conversion (TON < 2000) might be due to substrate evaporation in case of the volatile cyclohexane and inhibition of **1** in case of thioanisole.

Generally speaking, a maximum TON of 18933 (Table 1, substrate a) has been observed for *rAaeUPO*/**1** tandem-catalysed oxyfunctionalisation of ethylbenzene, which corresponds to roughly 45 g<sub>prod</sub> · g<sub>AaeUPO</sub><sup>−1</sup>. The TOF referred to the moles of **1** was in the range of 380 h<sup>−1</sup> and the total turnover number (TTON), which is defined as product mole per cofactor mole, was 4.8 that is in line with the values previously reported for Rh@PMO in combination with horse liver alcohol dehydrogenase (HLADH),<sup>[30]</sup> indicating that H<sub>2</sub>O<sub>2</sub> is catalytically generated in the combined reaction system.

## Conclusion

The potentiality of integrating organometallic and enzymatic catalysis has been herein demonstrated. The hybrid catalytic system comprising [Cp\*Ir(pica)NO<sub>3</sub>] **1**, to regenerate FMNH<sub>2</sub>

**Table 1.** Oxyfunctionalisation of substrates a–f by **1** and *rAaeUPO* catalytic tandem.<sup>[a]</sup>

Substrate	Product 1 (mM)	Product 2 (mM)	ee [%]	TON <sub>AaeUPO</sub>
	 16 ± 0.3	 3.1 ± 0.05	> 99 (R)	18933 ± 337
	 4.6 ± 0.1	 4.3 ± 0.08	> 99 (R)	8913 ± 232
	 12 ± 0.5	 4.0 ± 0.1	> 99 (R)	15702 ± 699
	 13 ± 0.7	–	> 99 (1R, 2S)	13488 ± 754
	 1.6 ± 0.5	 0.04 ± 0.1	n.d.	1634 ± 516
	 1.4	–	n.d.	1369 ± 136

[a] Experimental conditions: pH 7 by 0.4 M NaPi buffer containing 4% v/v MeOH; [HCOONa] = 0.2 M; [substrate] = 20 mM; [*rAaeUPO*] = 1.0 μM; [**1**] = 50 μM; [FMN] = 4 mM for **a** and **c** substrates, 1 mM for substrate **b**, **d**–**f**; T = 303 K. Data are expressed as the mean ± SD of the two independent experiments performed in technical duplicates.

from NaHCOO, and *rAaeUPO*, which, taking advantage of H<sub>2</sub>O<sub>2</sub> provided by the spontaneous reaction of formed FMNH<sub>2</sub> and O<sub>2</sub>, catalyses oxyfunctionalisation reactions, represents a proof-of-concept of the complementarity and synergistic effects of the two types of catalysis. At the same time, the results reported in this paper show that it is essential to conduct an in-depth optimisation study to understand under what conditions the two catalytic systems can work efficiently while minimising relative inhibitions. In this regard, it is reasonable to assume that immobilisation of one or both catalytic components can resolve or drastically mitigate their mutual inhibition by physical separation.<sup>[25b]</sup> Studies in this direction are ongoing in our laboratories. Envisioning preparative-scale application of the proposed reaction system will also necessitate reaction engineering to increase the overall substrate and product payload. Water-miscible cosolvents such as ACN used here do not appear suitable due to inhibitory effects. Future studies will rather concentrate on two liquid phase systems comprising the hydrophobic starting material as substrate reservoir and product sink.

## Experimental Section

**Enzyme preparation:** Recombinant expression and preparation of the evolved unspecific peroxidase from *A. aegerita rAaeUPO*

(PaDa-I mutant) in *P. pastoris* were performed following a previously described procedure.<sup>[27]</sup> The enzyme preparation used had a Reinheitszahl (Rz-value  $A_{418}/A_{280}$ ) of 0.6 and an UPO-concentration of 56 μM after one step of purification<sup>[6a]</sup> (Supporting information Figure S3). 20 mM phosphate buffer (pH 7) was used for storage of the enzyme at –20 °C.

**FMN reduction:** The reaction was monitored by UV-Vis spectroscopy, following the depletion of the absorption band of FMN centred at 455 nm ( $\epsilon = 10000 \text{ M}^{-1} \text{ cm}^{-1}$ ), using a Cary 60 UV VIS spectrophotometer (Agilent). In a typical experiment, 1 mL of a solution of FMN (0.1 mM in phosphate buffer (pH = 7, 0.4 M)) were transferred inside a cuvette. The system was allowed to equilibrate under stirring for 5 min at 298 K in N<sub>2</sub> atmosphere. After background correction, 15–30 μL of a solution of the catalyst was injected and data acquisition started. Turnover frequency [TOF = moles of FMNH<sub>2</sub>/(moles of catalyst per unit time)] values were obtained by deriving the TON versus t linear trends in the first 5% of reaction progress.

**Inactivation of **1** by *rAaeUPO*:** **1** (20 μM) was incubated in the presence of *rAaeUPO* (0.2–0.04 μM) in phosphate buffer at 25 °C. After 1, 5 and 24 h the mixtures were supplemented with FMN and analysed spectrophotometrically. Prior to the assay, the sample was equilibrated at the desired temperature under nitrogen for at least 2 minutes. The reaction was started by addition of formate. The values of turnover frequency were derived as above. Then, **1** residual activity is calculated as the ratio TOF/TOF<sub>0</sub>, where TOF<sub>0</sub> = 350 h<sup>–1</sup>.

**Inactivation of *rAaeUPO* by **1**:** *rAaeUPO* (0.5 μM) was incubated in phosphate buffer (0.4 M, pH 7) at 298 K with **1** (0–250 μM). After 1,

5 and 24 h the peroxidase activity of rAaeUPO was determined in a continuous photometric assay against the substrate 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) at 420 nm ( $\epsilon_{420} = 36.0 \text{ mM}^{-1} \text{ cm}^{-1}$ ). The incubation mixture was supplemented with 0.5 mM ABTS in 2 mL plastic cuvettes. After short incubation at 298 K, measurements were started by addition of 2 mM  $\text{H}_2\text{O}_2$ . The increase of absorption at 420 nm caused by ABTS formation was tracked spectrophotometrically. The initial slope ( $\Delta A_{420}/\text{min}$ ) between 20–80 s was linear and thus used to calculate the volumetric activity [U/mL]. Then, rAaeUPO residual activity is calculated as the ratio  $(\text{U/mL})/(\text{U/mL})_0$ , where  $(\text{U/mL})_0 = 21.8 \mu\text{M ABTSmin}^{-1} \text{ mL}^{-1}$ .

**Chemoenzymatic oxyfunctionalisation of ethylbenzene:** The reactions were performed in 2.0 mL glass vials placed in a thermomixer containing a solution of sodium phosphate buffer (0.4 M at pH 7) and 0.2 M sodium formate previously bubbled with air. After supplementation with rAaeUPO, FMN and ethyl benzene (10  $\mu\text{L}$  substrate in co-solvent), 250  $\mu\text{L}$  of reaction mixture was maintained at 298 K for some minutes. The reactions were started by the addition of 1 and incubated at 600 rpm in an Eppendorf shaker. Reactions were stopped by the addition of 250  $\mu\text{L}$  of n-heptane containing 5 mM n-octanol as internal standard with subsequent mixing. The product was extracted twice, and the obtained supernatant was analysed by GC-FID.

**Substrate scope:** The screening was performed in 0.4 M sodium phosphate buffer containing 0.2 M sodium formate at pH 7 in 2.0 mL glass vial. After supplementation with rAaeUPO, FMN and substrate (10  $\mu\text{L}$  methanol as co-solvent), 250  $\mu\text{L}$  of reaction mixture was maintained at 303 K for some minutes. The reactions were started by the addition of 1 and incubated at 600 rpm in an Eppendorf shaker. Reactions were terminated by the addition and subsequent mixing of 250  $\mu\text{L}$  of n-heptane or ethylacetate containing 5 mM n-octanol as internal standard. The reaction mixtures were extracted twice with the respective organic solvents and the obtained supernatant was analysed by GC-FID.

## Acknowledgements

Funded by the European Union (ERC, PeroxyZyme, No 101054658). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. C. D. thanks Erasmus + Traineeship program (KA1-2020-1-IT02-KA103-078486). C. D. and A. M. acknowledge the University of Perugia and MIUR (AMIS, "Dipartimenti di Eccellenza-2018–2022" program) for the financial support.

## Conflict of Interest

The authors declare no conflict of interest.

## Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

**Keywords:** chemoenzymatic tandem · FMN reduction · iridium · oxyfunctionalisation · peroxygenases

- [1] J. Dong, E. Fernández-Fueyo, F. Hollmann, C. Paul, M. Pesic, S. Schmidt, Y. Wang, S. Younes, W. Zhang, *Angew. Chem.* **2018**, *130*, 9380–9404, *Angew. Chem. Int. Ed.* **2018**, *57*, 9238–9261.
- [2] V. B. Urlacher, M. Girhard, *Trends Biotechnol.* **2019**, *37*, 882–897.
- [3] D. Holtmann, F. Hollmann, *ChemBioChem* **2016**, *17*, 1391–1398.
- [4] M. Hobisch, D. Holtmann, P. G. de Santos, M. Alcalde, F. Hollmann, S. Kara, *Biotechnol. Adv.* **2021**, *51*, 107615.
- [5] R. Ullrich, J. Nüske, K. Scheibner, J. Spantzel, M. Hofrichter, *Appl. Environ. Microbiol.* **2004**, *70*, 4575–4581.
- [6] a) P. Molina-Espeja, E. Garcia-Ruiz, D. Gonzalez-Perez, R. Ullrich, M. Hofrichter, M. Alcalde, *Appl. Environ. Microbiol.* **2014**, *80*, 3496–3507; b) P. Molina-Espeja, S. Ma, D. M. Mate, R. Ludwig, M. Alcalde, *Enz. Microb. Technol.* **2015**, *73–74*, 29–33.
- [7] B. Valderrama, M. Ayala, R. Vazquez-Duhalt, *Chem. Biol.* **2002**, *9*, 555–565.
- [8] B. O. O. Burek, S. Bormann, F. Hollmann, J. Bloh, D. Holtmann, *Green Chem.* **2019**, *21*, 3232–3249.
- [9] a) F. Tieves, S. J.-P. Willot, M. M. C. H. van Schie, M. C. R. Rauch, S. H. H. Younes, W. Zhang, P. G. de Santos, J. M. Robbins, B. Bommarius, M. Alcalde, A. Bommarius, F. Hollmann, *Angew. Chem.* **2019**, *131*, 7955–7959, *Angew. Chem. Int. Ed.* **2019**, *58*, 7873–7877; b) Y. Ni, E. Fernández-Fueyo, A. G. Baraibar, R. Ullrich, M. Hofrichter, H. Yanase, M. Alcalde, W. J. H. van Berkel, F. Hollmann, *Angew. Chem.* **2016**, *128*, 809–812, *Angew. Chem. Int. Ed.* **2016**, *55*, 798–801; c) J. Rocha-Martin, S. Velasco-Lozano, J. M. Guisan, F. Lopez-Gallego, *Green Chem.* **2014**, *16*, 303–311; d) Y. R. Li, Y. J. Ma, P. L. Li, X. Z. Zhang, D. Ribitsch, M. Alcalde, F. Hollmann, Y. H. Wang, *ChemPlusChem* **2020**, *85*, 254–257; e) P. G. de Santos, S. Lazaro, J. Viña-Gonzalez, M. D. Hoang, I. Sánchez-Moreno, A. Glieder, F. Hollmann, M. Alcalde, *ACS Catal.* **2020**, *10*, 13524–13534; f) A. Al-Shameri, S. J. P. Willot, C. E. Paul, F. Hollmann, L. Lauterbach, *Chem. Commun.* **2020**, *56*, 9667–9670.
- [10] a) C. H. Yun, J. Kim, F. Hollmann, C. B. Park, *Chem. Sci.* **2022**, *13*, 12260–12279; b) M. Mifsud, S. Gargiulo, S. Iborra, I. W. C. E. Arends, F. Hollmann, A. Corma, *Nat. Commun.* **2014**, *5*, 3145 ; c) E. Churakova, M. Kluge, R. Ullrich, I. Arends, M. Hofrichter, F. Hollmann, *Angew. Chem.* **2011**, *123*, 10904–10907, *Angew. Chem. Int. Ed.* **2011**, *50*, 10716–10719; d) D. I. Perez, M. Mifsud Grau, I. W. C. E. Arends, F. Hollmann, *Chem. Commun.* **2009**, *44*, 6848–6850.
- [11] a) C. Kohlmann, S. Lütz, *Eng. Life Sci.* **2006**, *6*, 170–174; b) S. Bormann, M. van Schie, T. P. De Almeida, W. Y. Zhang, M. Stockl, R. Ulber, F. Hollmann, D. Holtmann, *ChemSusChem* **2019**, *12*, 4759–4763; c) L. Getrey, T. Krieg, F. Hollmann, J. Schrader, D. Holtmann, *Green Chem.* **2014**, *16*, 1104–1108; d) T. Krieg, S. Huttmann, K.-M. Mangold, J. Schrader, D. Holtmann, *Green Chem.* **2011**, *13*, 2686–2689; e) A. E. W. Horst, S. Bormann, J. Meyer, M. Steinhagen, R. Ludwig, A. Drews, M. Ansorge-Schumacher, D. Holtmann, *J. Mol. Catal. B* **2016**, *133*, S137–S142.
- [12] a) S. J. Freakley, S. Kochius, J. van Marwijk, C. Fenner, R. J. Lewis, K. Baldenius, S. S. Marais, D. J. Opperman, S. T. L. Harrison, M. Alcalde, M. S. Smit, G. J. Hutchings, *Nat. Commun.* **2019**, *10*, 4178; b) F. Hollmann, A. Schmid, *J. Inorg. Biochem.* **2009**, *103*, 313–315.
- [13] a) J. Yoon, H. Jang, M.-W. Oh, T. Hilberath, F. Hollmann, Y. S. Jung, C. B. Park, *Nat. Commun.* **2022**, *13*, 3741; b) J. Kim, T. V. T. Nguyen, Y. H. Kim, F. Hollmann, C. B. Park, *Nat. Synth.* **2022**, *1*, 217–226; c) J. Kim, J. Jang, T. Hilberath, F. Hollmann, C. B. Park, *Nat. Synth.* **2022**, *1*, 776–786; d) Y. Zhang, H. Liu, M. M. C. H. van Schie, P.-L. Hagedoorn, M. Alcalde, A. G. Denkova, K. Djanashvili, F. Hollmann, *ACS Catal.* **2020**, *10*, 14195–14200; e) J. Yoon, J. Kim, F. Tieves, W. Y. Zhang, M. Alcalde, F. Hollmann, C. B. Park, *ACS Catal.* **2020**, *10*, 5236–5242; f) A. Yayci, A. G. Baraibar, M. Krewing, E. F. Fueyo, F. Hollmann, M. Alcalde, R. Kourist, J. E. Bandow, *ChemSusChem* **2020**, *13*, 2072–2079.
- [14] a) R. Kanega, N. Onishi, S. Tanaka, H. Kishimoto, Y. Himeda, *J. Am. Chem. Soc.* **2021**, *143*, 1570–1576; b) A. Nijamudheen, R. Kanega, N. Onishi, Y. Himeda, E. Fujita, M. Z. Ertem, *ACS Catal.* **2021**, *11*, 5776–5788; c) R. Kanega, N. Onishi, L. Wang, Y. Himeda, *ACS Catal.* **2018**, *8*, 11296–11301; d) L. Tensi, A. V. Yakimov, C. Trotta, C. Domestici, J. De Jesus Silva, S. R. Docherty, C. Zuccaccia, C. Copéret, A. Macchioni, *Inorg. Chem.* **2022**, *61*, 10575–10586.



- [15] a) A. Bucci, S. Dunn, G. Bellachioma, G. Menendez Rodriguez, C. Zuccaccia, C. Nervi, A. Macchioni, *ACS Catal.* **2017**, *11*, 7788–7796; b) L. Tensi, A. Macchioni, *ACS Catal.* **2020**, *10*, 7945–7949.
- [16] R. Kanega, N. Onishi, D. J. Szalda, M. Z. Ertem, J. T. Muckerman, E. Fujita, Y. Himeda, *ACS Catal.* **2017**, *7*, 6426–6429.
- [17] a) A. H. Ngo, M. Ibañez, L. H. Do, *ACS Catal.* **2016**, *6*, 2637–2641; b) S. Bose, A. H. Ngo, L. H. Do, *J. Am. Chem. Soc.* **2017**, *139*, 8792–8795.
- [18] a) R. Kanega, N. Onishi, L. Wang, K. Murata, J. T. Muckerman, E. Fujita, Y. Himeda, *Chem. Eur. J.* **2018**, *24*, 18389–18392; b) G. Menendez Rodriguez, C. Domestici, A. Bucci, M. Valentini, C. Zuccaccia, A. Macchioni, *Eur. J. Inorg. Chem.* **2018**, *2018*, 2247–2250; c) G. Menendez Rodriguez, F. Zaccaria, L. Tensi, C. Zuccaccia, P. Belanzoni, A. Macchioni, *Chem. Eur. J.* **2021**, *27*, 2050–2064.
- [19] a) M. Watanabe, J. Hori, K. Murata, *EP 2228377* **2010**; b) C. K. Hill, J. F. Hartwig, *Nat. Chem.* **2017**, *9*, 1213–1221; c) K. Tanaka, T. Miki, K. Murata, A. Yamaguchi, Y. Kayaki, S. Kuwata, T. Ikariya, M. Watanabe, *J. Org. Chem.* **2019**, *84*, 10962–10977; d) D. P. Nguyen, R. N. Sladek, L. H. Do, *Tet. Lett.* **2020**, *61*, 152196.
- [20] T. Beppu, K. Sakamoto, Y. Nakajima, K. Matsumoto, K. Sato, S. Shimada, *J. Organomet. Chem.* **2018**, *869*, 75–80.
- [21] H. T. H. Nguyen, L. H. Do, *Chem. Commun.* **2020**, *56*, 13381–13384.
- [22] a) T. J. Kotzé, S. Duffy, V. M. Avery, A. Jordaan, D. F. Warner, L. Loots, G. S. Smith, P. Chellan, *Inorg. Chim. Acta* **2021**, *517*, 120175; b) Z. Almodares, S. J. Lucas, B. D. Crossley, A. M. Basri, C. M. Pask, A. J. Hebden, R. M. Phillips, P. C. McGowan, *Inorg. Chem.* **2014**, *53*, 727–736; c) N. R. Palepu, J. Richard Premkumar, A. K. Verma, K. Bhattacharjee, S. R. Joshi, S. Forbes, Y. Mozharivskij, K. Mohan Rao, *Arab. J. Chem.* **2018**, *11*, 714–728; d) S. J. Lucas, R. M. Lord, A. M. Basri, S. J. Allison, R. M. Phillips, A. J. Blacker, P. C. McGowan, *Dalton Trans.* **2016**, *45*, 6812–6815.
- [23] F. Hollmann, B. Witholt, A. Schmid, *J. Mol. Catal. B* **2002**, *19–20*, 167–176.
- [24] S. Shibata, T. Suenobu, S. Fukuzumi, *Angew. Chem.* **2013**, *125*, 12553–12557, *Angew. Chem. Int. Ed.* **2013**, *52*, 12327–12331.
- [25] a) M. Poizat, I. W. C. E. Arends, F. Hollmann, *J. Mol. Catal. B. Enzym.* **2010**, *63*, 149–156; b) F. Hildebrand, S. Lütz, *Chem. Eur. J.* **2009**, *15*, 4998–5001.
- [26] F. E. H. Nintzel, Y. Wu, M. Planchestainer, M. Held, M. Alcalde, F. Hollmann, *Chem. Commun.* **2021**, *57*, 5766–5769.
- [27] F. Tonin, F. Tieves, S. Willot, A. van Troost, R. van Oosten, S. Breesstraet, S. van Pelt, M. Alcalde, F. Hollmann, *Org. Process Res. Dev.* **2021**, *25*, 1414–1418.
- [28] M. Kluge, R. Ullrich, K. Scheibner, M. Hofrichter, *Green Chem.* **2012**, *14*, 440–446.
- [29] T. Hilberath, A. van Troost, M. Alcalde, F. Hollmann, *Frontiers in Catalysis* **2022**, *2*, 882992 .
- [30] T. Himiyama, M. Waki, Y. Maegawa, S. Inagaki, *Angew. Chem.* **2019**, *131*, 9248–9252, *Angew. Chem. Int. Ed.* **2019**, *58*, 9150–9154.

---

Manuscript received: December 19, 2022  
Revised manuscript received: March 8, 2023  
Accepted manuscript online: March 8, 2023  
Version of record online: March 24, 2023